{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T01:20:33Z","timestamp":1792113633916,"version":"4.4.0"},"reference-count":92,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Nonalcoholic fatty liver disease (NAFLD) is a prevalent cause of liver disease and metabolic comorbidities. Obesity is strongly associated with NAFLD and is also a state of relative deficiency of growth hormone (GH). Evidence supports a role of reduced GH and insulin-like growth factor-1 (IGF-1) in NAFLD pathogenesis. Physiological actions of GH in the liver include suppression of de novo lipogenesis (DNL) and promotion of lipid beta-oxidation, and GH also appears to have anti-inflammatory actions. Physiologic actions of IGF-1 include suppression of inflammatory and fibrogenic pathways important in the evolution from steatosis to steatohepatitis and fibrosis. Rodent models of impaired hepatic GH signaling show the development of steatosis, sometimes accompanied by inflammation, hepatocellular damage, and fibrosis, and these changes are ameliorated by treatment with GH and\/or IGF-1. In humans, individuals with GH deficiency and GH resistance demonstrate an increased prevalence of NAFLD compared to controls, with improvement in hepatic lipid, steatohepatitis, and fibrosis following GH replacement. As a corollary, individuals with GH excess demonstrate lower hepatic lipid compared to controls along with increased hepatic lipid following treatment to normalize GH levels. Clinical trials demonstrate that augmentation of GH reduces hepatic lipid content in individuals with NAFLD and may also ameliorate steatohepatitis and fibrosis. Taken together, evidence supports an important role for perturbations in the GH\/IGF-1 axis as one of the pathogenic mechanisms of NAFLD and suggests that further study is needed to assess whether augmentation of GH and\/or IGF-1 may be a safe and effective therapeutic strategy for NAFLD.<\/jats:p>","DOI":"10.1097\/in9.0000000000000030","type":"journal-article","created":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T15:53:32Z","timestamp":1690386812000},"page":"e00030","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":19,"title":["Growth hormone and nonalcoholic fatty liver disease"],"prefix":"10.1097","volume":"5","author":[{"given":"Ingrid L.","family":"Ma","sequence":"first","affiliation":[{"name":"Metabolism Unit, Endocrine Division, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takara L.","family":"Stanley","sequence":"additional","affiliation":[{"name":"Metabolism Unit, Endocrine Division, Massachusetts General Hospital, Boston, MA, USA"},{"name":"Pediatric Endocrine Division, Massachusetts General Hospital, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,7]]},"reference":[{"issue":"2","key":"R1-20240826","doi-asserted-by":"crossref","first-page":"101215","DOI":"10.1016\/j.diabet.2020.101215","article-title":"NAFLD, and cardiovascular and cardiac diseases: Factors influencing risk, prediction and treatment.","volume":"47","author":"Targher","year":"2021","journal-title":"Diabetes Metab"},{"issue":"2","key":"R2-20240826","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/03602532.2017.1293683","article-title":"Non-alcoholic fatty liver disease (NAFLD) \u2013 pathogenesis, classification, and effect on drug metabolizing enzymes and transporters.","volume":"49","author":"Cobbina","year":"2017","journal-title":"Drug Metab Rev"},{"issue":"1","key":"R3-20240826","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"2","key":"R4-20240826","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/j.jhep.2021.02.034","article-title":"Prospective evaluation of the prevalence of non-alcoholic fatty liver disease and steatohepatitis in a large middle-aged US cohort.","volume":"75","author":"Harrison","year":"2021","journal-title":"J Hepatol"},{"issue":"4","key":"R5-20240826","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S2213-8587(22)00003-1","article-title":"A global view of the interplay between non-alcoholic fatty liver disease and diabetes.","volume":"10","author":"Stefan","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"10","key":"R6-20240826","doi-asserted-by":"crossref","first-page":"e0140908","DOI":"10.1371\/journal.pone.0140908","article-title":"The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis.","volume":"10","author":"Anderson","year":"2015","journal-title":"PLoS One"},{"issue":"3","key":"R7-20240826","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1053\/j.gastro.2014.11.039","article-title":"Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States.","volume":"148","author":"Wong","year":"2015","journal-title":"Gastroenterology"},{"issue":"1","key":"R8-20240826","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases.","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"issue":"11","key":"R9-20240826","doi-asserted-by":"crossref","first-page":"4254","DOI":"10.1210\/jc.2008-1333","article-title":"The effects of central adiposity on growth hormone (GH) response to GH-releasing hormone-arginine stimulation testing in men.","volume":"93","author":"Makimura","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"R10-20240826","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1210\/jc.2004-0894","article-title":"Truncal adiposity, relative growth hormone deficiency, and cardiovascular risk.","volume":"90","author":"Miller","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"R11-20240826","doi-asserted-by":"crossref","first-page":"E385","DOI":"10.1152\/ajpendo.00052.2008","article-title":"Lower growth hormone and higher cortisol are associated with greater visceral adiposity, intramyocellular lipids, and insulin resistance in overweight girls.","volume":"295","author":"Misra","year":"2008","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"6","key":"R12-20240826","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1210\/en.2005-1549","article-title":"Impact of obesity on the growth hormone axis: evidence for a direct inhibitory effect of hyperinsulinemia on pituitary function.","volume":"147","author":"Luque","year":"2006","journal-title":"Endocrinology"},{"issue":"4","key":"R13-20240826","doi-asserted-by":"crossref","first-page":"R693","DOI":"10.1152\/ajpregu.00595.2003","article-title":"Acipimox enhances spontaneous growth hormone secretion in obese women.","volume":"286","author":"Kok","year":"2004","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"issue":"9","key":"R14-20240826","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1001\/jamainternmed.2019.2248","article-title":"Association of weight loss interventions with changes in biomarkers of nonalcoholic fatty liver disease: a systematic review and meta-analysis.","volume":"179","author":"Koutoukidis","year":"2019","journal-title":"JAMA Intern Med"},{"issue":"1","key":"R15-20240826","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jhep.2012.02.023","article-title":"Exercise and non-alcoholic fatty liver disease: a systematic review and meta-analysis.","volume":"57","author":"Keating","year":"2012","journal-title":"J Hepatol"},{"issue":"3","key":"R16-20240826","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.gastro.2020.11.051","article-title":"AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review.","volume":"160","author":"Younossi","year":"2021","journal-title":"Gastroenterology"},{"issue":"4","key":"R17-20240826","doi-asserted-by":"crossref","first-page":"562","DOI":"10.3390\/ijms17040562","article-title":"NAFLD and chronic kidney disease.","volume":"17","author":"Marcuccilli","year":"2016","journal-title":"Int J Mol Sci"},{"issue":"4500","key":"R18-20240826","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1126\/science.6262917","article-title":"Somatomedin-C mediates growth hormone negative feedback by effects on both the hypothalamus and the pituitary.","volume":"212","author":"Berelowitz","year":"1981","journal-title":"Science"},{"issue":"2","key":"R19-20240826","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0006-8993(98)01286-4","article-title":"Insulin-like growth factor-1 (IGF-1)-induced inhibition of growth hormone secretion is associated with sleep suppression.","volume":"818","author":"Obal","year":"1999","journal-title":"Brain Res"},{"issue":"10","key":"R20-20240826","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.3390\/cells10102532","article-title":"Towards understanding the direct and indirect actions of growth hormone in controlling hepatocyte carbohydrate and lipid metabolism.","volume":"10","author":"Vazquez-Borrego","year":"2021","journal-title":"Cells"},{"key":"R21-20240826","doi-asserted-by":"crossref","first-page":"636403","DOI":"10.3389\/fendo.2021.636403","article-title":"The complex world of regulation of pituitary growth hormone secretion: the Role of Ghrelin, Klotho, and Nesfatins in It.","volume":"12","author":"Devesa","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"7","key":"R22-20240826","doi-asserted-by":"crossref","first-page":"e100822","DOI":"10.1371\/journal.pone.0100822","article-title":"Reliable quantification of protein expression and cellular localization in histological sections.","volume":"9","author":"Schlederer","year":"2014","journal-title":"PLoS One"},{"key":"R23-20240826","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.ghir.2015.09.002","article-title":"Growth hormone signaling pathways.","volume":"28","author":"Carter-Su","year":"2016","journal-title":"Growth Horm IGF Res"},{"key":"R24-20240826","doi-asserted-by":"crossref","first-page":"154569","DOI":"10.1016\/j.cyto.2018.10.010","article-title":"Hepatic growth hormone-JAK2-STAT5 signalling: metabolic function, non-alcoholic fatty liver disease and hepatocellular carcinoma progression.","volume":"124","author":"Kaltenecker","year":"2019","journal-title":"Cytokine"},{"key":"R25-20240826","doi-asserted-by":"crossref","first-page":"110788","DOI":"10.1016\/j.mce.2020.110788","article-title":"Regulation of gene expression by growth hormone.","volume":"507","author":"Rotwein","year":"2020","journal-title":"Mol Cell Endocrinol"},{"issue":"4","key":"R26-20240826","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/hep.24509","article-title":"Impairment of hepatic growth hormone and glucocorticoid receptor signaling causes steatosis and hepatocellular carcinoma in mice.","volume":"54","author":"Mueller","year":"2011","journal-title":"Hepatology"},{"issue":"7","key":"R27-20240826","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.3390\/ijms18071447","article-title":"The role of growth hormone and insulin-like growth factor-I in the liver.","volume":"18","author":"Takahashi","year":"2017","journal-title":"Int J Mol Sci"},{"key":"R28-20240826","doi-asserted-by":"crossref","first-page":"101482","DOI":"10.1016\/j.ghir.2022.101482","article-title":"Expression of IGF-1 receptor and GH receptor in hepatic tissue of patients with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.","volume":"65","author":"Osganian","year":"2022","journal-title":"Growth Horm IGF Res"},{"issue":"9","key":"R29-20240826","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1002\/hep4.1953","article-title":"Growth hormone deficiency and NAFLD: An overlooked and underrecognized link.","volume":"6","author":"Doycheva","year":"2022","journal-title":"Hepatol Commun"},{"issue":"16","key":"R30-20240826","doi-asserted-by":"crossref","first-page":"e140134","DOI":"10.1172\/jci.insight.140134","article-title":"Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD.","volume":"5","author":"Fourman","year":"2020","journal-title":"JCI Insight"},{"issue":"12","key":"R31-20240826","first-page":"4208","article-title":"Stimulation of mitochondrial fatty acid oxidation by growth hormone in human fibroblasts.","volume":"82","author":"Leung","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"R32-20240826","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1210\/er.2008-0027","article-title":"Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects.","volume":"30","author":"Moller","year":"2009","journal-title":"Endocr Rev"},{"key":"R33-20240826","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1210\/endo-72-1-95","article-title":"Effects of chronic growth hormone treatment on lipogenesis by rat adipose tissue.","volume":"72","author":"Goodman","year":"1963","journal-title":"Endocrinology"},{"issue":"2","key":"R34-20240826","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0303-7207(84)90057-1","article-title":"Effects of growth hormone on lipogenesis and glucose oxidation in genetically GH-deficient mice.","volume":"37","author":"Adamafio","year":"1984","journal-title":"Mol Cell Endocrinol"},{"issue":"5","key":"R35-20240826","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1210\/endo-56-5-579","article-title":"The effect of growth hormone on lipogenesis in intact and adrenalectomized rats.","volume":"56","author":"Perry","year":"1955","journal-title":"Endocrinology"},{"issue":"1","key":"R36-20240826","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1677\/jme.0.0040043","article-title":"Effects of exogenous growth hormone on lipid metabolism in the isolated epididymal fat pad of the growth hormone-deficient little mouse.","volume":"4","author":"Ng","year":"1990","journal-title":"J Mol Endocrinol"},{"issue":"1","key":"R37-20240826","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1677\/joe.0.1500129","article-title":"GH inhibition of lipogenesis and stimulation of lipolysis in sheep adipose tissue: involvement of protein serine phosphorylation and dephosphorylation and phospholipase C.","volume":"150","author":"Vernon","year":"1996","journal-title":"J Endocrinol"},{"issue":"2","key":"R38-20240826","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1210\/jcem.87.2.8391","article-title":"Effects of recombinant human growth hormone on hepatic lipid and carbohydrate metabolism in HIV-infected patients with fat accumulation.","volume":"87","author":"Schwarz","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"R39-20240826","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease.","volume":"115","author":"Donnelly","year":"2005","journal-title":"J Clin Invest"},{"issue":"7","key":"R40-20240826","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1210\/en.2010-1193","article-title":"GH receptor plays a major role in liver regeneration through the control of EGFR and ERK1\/2 activation.","volume":"152","author":"Zerrad-Saadi","year":"2011","journal-title":"Endocrinology"},{"issue":"2","key":"R41-20240826","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1002\/hep.31297","article-title":"Growth hormone stops excessive inflammation after partial hepatectomy, allowing liver regeneration and survival through induction of H2-Bl\/HLA-G.","volume":"73","author":"Ishikawa","year":"2021","journal-title":"Hepatology"},{"issue":"4","key":"R42-20240826","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1084\/jem.20080003","article-title":"Loss of STAT5 causes liver fibrosis and cancer development through increased TGF-beta and STAT3 activation.","volume":"206","author":"Hosui","year":"2009","journal-title":"J Exp Med"},{"issue":"5","key":"R43-20240826","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1002\/hep.23882","article-title":"The transcription factors signal transducer and activator of transcription 5A (STAT5A) and STAT5B negatively regulate cell proliferation through the activation of cyclin-dependent kinase inhibitor 2b (Cdkn2b) and Cdkn1a expression.","volume":"52","author":"Yu","year":"2010","journal-title":"Hepatology"},{"issue":"3","key":"R44-20240826","first-page":"912","article-title":"Insulin-like growth factor I gene transfer to cirrhotic liver induces fibrolysis and reduces fibrogenesis leading to cirrhosis reversion in rats.","volume":"51","author":"Sobrevals","year":"2010","journal-title":"Hepatology"},{"issue":"2","key":"R45-20240826","doi-asserted-by":"crossref","first-page":"E304","DOI":"10.1210\/jc.2012-3290","article-title":"Insulin-like growth factor-I, inflammatory proteins, and fibrosis in subjects with nonalcoholic fatty liver disease.","volume":"98","author":"Hribal","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"R46-20240826","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1089\/scd.2014.0174","article-title":"Mesenchymal stromal cells engineered to produce IGF-I by recombinant adenovirus ameliorate liver fibrosis in mice.","volume":"24","author":"Fiore","year":"2015","journal-title":"Stem Cells Dev"},{"issue":"1","key":"R47-20240826","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1136\/gut.2003.024505","article-title":"Expression of insulin-like growth factor I by activated hepatic stellate cells reduces fibrogenesis and enhances regeneration after liver injury.","volume":"54","author":"Sanz","year":"2005","journal-title":"Gut"},{"key":"R48-20240826","doi-asserted-by":"crossref","first-page":"34605","DOI":"10.1038\/srep34605","article-title":"IGF-I induces senescence of hepatic stellate cells and limits fibrosis in a p53-dependent manner.","volume":"6","author":"Nishizawa","year":"2016","journal-title":"Sci Rep"},{"issue":"2","key":"R49-20240826","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1002\/hep.21713","article-title":"Loss of signal transducer and activator of transcription 5 leads to hepatosteatosis and impaired liver regeneration.","volume":"46","author":"Cui","year":"2007","journal-title":"Hepatology"},{"issue":"30","key":"R50-20240826","doi-asserted-by":"crossref","first-page":"19937","DOI":"10.1074\/jbc.M109.014308","article-title":"Liver-specific deletion of the growth hormone receptor reveals essential role of growth hormone signaling in hepatic lipid metabolism.","volume":"284","author":"Fan","year":"2009","journal-title":"J Biol Chem"},{"issue":"4","key":"R51-20240826","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1172\/JCI42894","article-title":"Abrogation of growth hormone secretion rescues fatty liver in mice with hepatocyte-specific deletion of JAK2.","volume":"121","author":"Sos","year":"2011","journal-title":"J Clin Invest"},{"issue":"1","key":"R52-20240826","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1210\/en.2010-0537","article-title":"GH-dependent STAT5 signaling plays an important role in hepatic lipid metabolism.","volume":"152","author":"Barclay","year":"2011","journal-title":"Endocrinology"},{"issue":"13","key":"R53-20240826","doi-asserted-by":"crossref","first-page":"10277","DOI":"10.1074\/jbc.M111.317453","article-title":"Hepatocyte-specific deletion of Janus kinase 2 (JAK2) protects against diet-induced steatohepatitis and glucose intolerance.","volume":"287","author":"Shi","year":"2012","journal-title":"J Biol Chem"},{"issue":"2","key":"R54-20240826","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.bbrc.2012.05.115","article-title":"GH-independent IGF-I action is essential to prevent the development of nonalcoholic steatohepatitis in a GH-deficient rat model.","volume":"423","author":"Nishizawa","year":"2012","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"R55-20240826","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1210\/en.2013-2086","article-title":"Liver-specific GH receptor gene-disrupted (LiGHRKO) mice have decreased endocrine IGF-I, increased local IGF-I, and altered body size, body composition, and adipokine profiles.","volume":"155","author":"List","year":"2014","journal-title":"Endocrinology"},{"issue":"12","key":"R56-20240826","doi-asserted-by":"crossref","first-page":"3598","DOI":"10.2337\/db16-0649","article-title":"Growth hormone control of hepatic lipid metabolism.","volume":"65","author":"Liu","year":"2016","journal-title":"Diabetes"},{"issue":"11","key":"R57-20240826","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1210\/me.2006-0007","article-title":"Growth hormone regulation of sex-dependent liver gene expression.","volume":"20","author":"Waxman","year":"2006","journal-title":"Mol Endocrinol"},{"issue":"10","key":"R58-20240826","first-page":"1325","article-title":"The effect of low and high plasma levels of insulin-like growth factor-1 (IGF-1) on the morphology of major organs: studies of Laron dwarf and bovine growth hormone transgenic (bGHTg) mice.","volume":"28","author":"Piotrowska","year":"2013","journal-title":"Histol Histopathol"},{"issue":"8","key":"R59-20240826","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1210\/me.2013-1110","article-title":"Disruption of JAK2 in adipocytes impairs lipolysis and improves fatty liver in mice with elevated GH.","volume":"27","author":"Nordstrom","year":"2013","journal-title":"Mol Endocrinol"},{"key":"R60-20240826","doi-asserted-by":"crossref","first-page":"34719","DOI":"10.1038\/srep34719","article-title":"Hepatic deletion of Janus Kinase 2 counteracts oxidative stress in mice.","volume":"6","author":"Themanns","year":"2016","journal-title":"Sci Rep"},{"key":"R61-20240826","doi-asserted-by":"crossref","first-page":"154576","DOI":"10.1016\/j.phymed.2022.154576","article-title":"Integrative multi-omics unravels the amelioration effects of Zanthoxylum bungeanum Maxim. on non-alcoholic fatty liver disease.","volume":"109","author":"Huang","year":"2023","journal-title":"Phytomedicine"},{"issue":"12","key":"R62-20240826","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1055\/a-1941-8556","article-title":"Metabolic profile and echocardiographic evaluation in adults with growth hormone deficiency.","volume":"54","author":"Yang","year":"2022","journal-title":"Horm Metab Res"},{"issue":"11","key":"R63-20240826","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.eprac.2021.06.003","article-title":"High prevalence of nonalcoholic fatty liver disease among adolescents and young adults with hypopituitarism due to growth hormone deficiency.","volume":"27","author":"Kang","year":"2021","journal-title":"Endocr Pract"},{"issue":"4","key":"R64-20240826","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/hep.20140","article-title":"Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction.","volume":"39","author":"Adams","year":"2004","journal-title":"Hepatology"},{"issue":"6","key":"R65-20240826","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1136\/gut.52.6.914","article-title":"Non-alcoholic steatohepatitis and hepatic steatosis in patients with adult onset growth hormone deficiency.","volume":"52","author":"Ichikawa","year":"2003","journal-title":"Gut"},{"issue":"1","key":"R66-20240826","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1530\/EJE-12-0252","article-title":"Nonalcoholic fatty liver disease in adult hypopituitary patients with GH deficiency and the impact of GH replacement therapy.","volume":"167","author":"Nishizawa","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"R67-20240826","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ghir.2014.07.002","article-title":"Long-term effects of growth hormone replacement therapy on liver function in adult patients with growth hormone deficiency.","volume":"24","author":"Matsumoto","year":"2014","journal-title":"Growth Horm IGF Res"},{"issue":"5","key":"R68-20240826","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.ghir.2008.03.003","article-title":"Nonalcoholic fatty liver in patients with Laron syndrome and GH gene deletion \u2013 preliminary report.","volume":"18","author":"Laron","year":"2008","journal-title":"Growth Horm IGF Res"},{"issue":"11","key":"R69-20240826","doi-asserted-by":"crossref","first-page":"4218","DOI":"10.1210\/jc.2017-01210","article-title":"Body composition and ectopic lipid changes with biochemical control of acromegaly.","volume":"102","author":"Bredella","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"R70-20240826","doi-asserted-by":"crossref","first-page":"e134638","DOI":"10.1172\/jci.insight.134638","article-title":"Increased ATP synthesis might counteract hepatic lipid accumulation in acromegaly.","volume":"5","author":"Fellinger","year":"2020","journal-title":"JCI Insight"},{"issue":"8","key":"R71-20240826","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1210\/jc.2015-1917","article-title":"Adipose tissue redistribution and ectopic lipid deposition in active acromegaly and effects of surgical treatment.","volume":"100","author":"Reyes-Vidal","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"R72-20240826","doi-asserted-by":"crossref","first-page":"bvab004","DOI":"10.1210\/jendso\/bvab004","article-title":"Body composition changes with long-term pegvisomant therapy of acromegaly.","volume":"5","author":"Kuker","year":"2021","journal-title":"J Endocr Soc"},{"issue":"2","key":"R73-20240826","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1055\/s-0043-118911","article-title":"Impairment of GH\/IGF-1 axis in the liver of patients with HCV-related chronic hepatitis.","volume":"50","author":"Carotti","year":"2018","journal-title":"Horm Metab Res"},{"issue":"2","key":"R74-20240826","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/hep.27408","article-title":"Growth hormone resistance exacerbates cholestasis-induced murine liver fibrosis.","volume":"61","author":"Stiedl","year":"2015","journal-title":"Hepatology"},{"issue":"4","key":"R75-20240826","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1365-2265.2011.04291.x","article-title":"Nonalcoholic fatty liver disease is associated with increased GHBP and reduced GH\/IGF-I levels.","volume":"77","author":"Fusco","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"9","key":"R76-20240826","doi-asserted-by":"crossref","first-page":"e3624","DOI":"10.1210\/clinem\/dgac405","article-title":"The GH\/IGF-1 axis is associated with intrahepatic lipid content and hepatocellular damage in overweight\/obesity.","volume":"107","author":"Dichtel","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"R77-20240826","doi-asserted-by":"crossref","first-page":"E1640","DOI":"10.1210\/jc.2011-1227","article-title":"Nonalcoholic fatty liver disease is associated with low circulating levels of insulin-like growth factor-I.","volume":"96","author":"Arturi","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"R78-20240826","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1111\/hepr.12408","article-title":"Lower levels of insulin-like growth factor-1 standard deviation score are associated with histological severity of non-alcoholic fatty liver disease.","volume":"45","author":"Sumida","year":"2015","journal-title":"Hepatol Res"},{"issue":"5","key":"R79-20240826","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1530\/EJE-09-0374","article-title":"Association between hepatic steatosis and serum IGF1 and IGFBP-3 levels in a population-based sample.","volume":"161","author":"Volzke","year":"2009","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"R80-20240826","doi-asserted-by":"crossref","first-page":"e217","DOI":"10.1038\/ctg.2016.72","article-title":"The association between IGF-1 levels and the histologic severity of nonalcoholic fatty liver disease.","volume":"8","author":"Dichtel","year":"2017","journal-title":"Clin Transl Gastroenterol"},{"issue":"5","key":"R81-20240826","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2169\/internalmedicine.56.7626","article-title":"The relationship between the growth hormone\/insulin-like growth factor system and the histological features of nonalcoholic fatty liver disease.","volume":"56","author":"Chishima","year":"2017","journal-title":"Intern Med"},{"issue":"5","key":"R82-20240826","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1007\/s12072-018-9893-7","article-title":"Metabolic effects of reduced growth hormone action in fatty liver disease.","volume":"12","author":"Rufinatscha","year":"2018","journal-title":"Hepatol Int"},{"issue":"2","key":"R83-20240826","doi-asserted-by":"crossref","first-page":"e520","DOI":"10.1210\/clinem\/dgaa792","article-title":"Relationship of IGF-1 and IGF-binding proteins to disease severity and glycemia in nonalcoholic fatty liver disease.","volume":"106","author":"Stanley","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"23","key":"R84-20240826","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1056\/NEJMoa072375","article-title":"Metabolic effects of a growth hormone-releasing factor in patients with HIV.","volume":"357","author":"Falutz","year":"2007","journal-title":"N Engl J Med"},{"issue":"9","key":"R85-20240826","doi-asserted-by":"crossref","first-page":"4291","DOI":"10.1210\/jc.2010-0490","article-title":"Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data.","volume":"95","author":"Falutz","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"R86-20240826","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1001\/jama.2014.8334","article-title":"Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.","volume":"312","author":"Stanley","year":"2014","journal-title":"JAMA"},{"issue":"12","key":"R87-20240826","doi-asserted-by":"crossref","first-page":"e821","DOI":"10.1016\/S2352-3018(19)30338-8","article-title":"Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.","volume":"6","author":"Stanley","year":"2019","journal-title":"Lancet HIV"},{"issue":"4","key":"R88-20240826","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1093\/cid\/ciab019","article-title":"Growth hormone releasing hormone reduces circulating markers of immune activation in parallel with effects on hepatic immune pathways in individuals with HIV-infection and nonalcoholic fatty liver disease.","volume":"73","author":"Stanley","year":"2021","journal-title":"Clin Infect Dis"},{"issue":"9","key":"R89-20240826","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1210\/jc.2013-2063","article-title":"Effects of GH on body composition and cardiovascular risk markers in young men with abdominal obesity.","volume":"98","author":"Bredella","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"R90-20240826","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/cen.14344","article-title":"Effect of recombinant human growth hormone on liver fat content in young adults with nonalcoholic fatty liver disease.","volume":"94","author":"Pan","year":"2021","journal-title":"Clin Endocrinol (Oxf)"},{"key":"R91-20240826","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgad375","article-title":"Growth hormone administration improves nonalcoholic fatty liver disease in overweight\/obesity: a randomized trial.","author":"Dichtel","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"R92-20240826","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s12072-019-09970-3","article-title":"Reversal of NASH fibrosis with pharmacotherapy.","volume":"13","author":"Alukal","year":"2019","journal-title":"Hepatol Int"}],"container-title":["Immunometabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IN9.0000000000000030","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,26]],"date-time":"2024-08-26T13:33:20Z","timestamp":1724679200000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IN9.0000000000000030"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":92,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/in9.0000000000000030","relation":{},"ISSN":["2633-0407"],"issn-type":[{"value":"2633-0407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7]]}}}